Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET
Company Participants
Jenna Cohen - Vice President-Investor Relations
Kate Haviland - Chief Executive Officer
Philina Lee - Chief Commercial Officer
Christy Rossi - Chief Operating Officer
Mike Landsittel - Chief Financial Officer
Fouad Namouni - President-Research & Development
Conference Call Participants
Marc Frahm - TD Cowen
Brad Canino - Stifel
Reni Benjamin - Citizens JMP
Paul Jeng - Guggenheim
Tommie Reerink - Goldman Sachs
Derek Archila - Wells Fargo
Mike Ulz - Morgan Stanley
Ami Fadia - Needham
Markus Schweiger - Oppenheimer
Peter Lawson - Barclays
Laura Prendergast - Raymond James
David Lebowitz - Citi
Sudan Loganathan - Stephens
Operator
Good morning. My name is Nadia, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] Thank you.
Jenna Cohen, you may begin your conference.
Jenna Cohen
Thank you, Nadia. Good morning, everyone. And welcome to Blueprint Medicines third quarter 2024 financial and operating results conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
Joining me today are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer; Christy Rossi, Chief Operating Officer; and Mike Landsittel, Chief Financial Officer. Fouad Namouni, President, Research and Development, is also on the line and available during Q&A.
Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements as outlined on Slide 3 and are subject to a number of risks and uncertainties. These may cause our actual results to differ materially, including those described in our reports filed with the SEC. You're cautioned not to place any undue reliance on these forward-looking statements, and Blueprint disclaims any obligation to update such statements.
I'll now hand the call over to Kate.
Kate Haviland
Thank you, Jenna. And good morning, everyone.
This morning, we reported another strong quarter of AYVAKIT revenue growth, adding additional momentum to our impressive year-to-date results and providing a strong foundation for us to drive long-term shareholder value creation in 2025 and beyond. AYVAKIT's sales trajectory has given us the confidence to raise our revenue expectations significantly over the course of this year.